House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Pain medicine

Chronic pelvic pain

EAU · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

EAU chronic pelvic pain guidance uses a biopsychosocial, multidisciplinary approach after investigating treatable disease. It distinguishes primary prostate, bladder, anorectal, pelvic-floor and neuropathic pain phenotypes, rather than assuming that every pelvic symptom arises from one organ. Treatment aims include function, relationships and quality of life as well as pain relief, with shared decisions and planned reassessment.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Investigate disease and understand the pain phenotype

  • Diagnose a primary pelvic pain syndrome only after excluding relevant disease, with symptoms present for at least three months. Consider infection, malignancy, drug-related injury such as ketamine, anatomical or functional pelvic-organ disease and neurological causes rather than assuming unexplained pain is benign. [1]
  • Assess function, emotional distress, sexual effects, work and social life alongside pain. Use validated symptom and quality-of-life measures for baseline and follow-up; for primary prostate pain, NIH-CPSI is an example. A pain diary may record voiding, sexual activity, activity and analgesic use. [1]
  • Explain the purpose and possible pain flare before rectal or vaginal examination, obtain consent and discuss a chaperone. Include relevant musculoskeletal and neurological assessment and look for pelvic-floor dysfunction or trigger points; tailor examination to findings that could change management. [1]
  • Suspect primary bladder pain syndrome when bladder-related pain, pressure or discomfort accompanies another symptom such as increased urinary frequency, after confusable disease is excluded. Obtain urine testing and culture, with tuberculosis culture for sterile pyuria and cytology in risk groups; EAU recommends rigid cystoscopy under general anaesthesia to subtype and exclude alternative disease. [1]
  • After continence or prolapse mesh, take a full uro-gynaecological history and consider specialist imaging. If a gynaecological cause is suspected after urological assessment, refer to gynaecology; decisions about laparoscopy should follow the relevant gynaecological guidance. [1]

Use selected treatment for primary prostate pain

  • For primary prostate pain syndrome, offer multimodal treatment directed at the symptom phenotype, a weak recommendation. Address urinary, sexual and psychosocial consequences and select therapy with the patient rather than relying on a single organ-directed intervention. [1]
  • EAU recommends a quinolone or tetracycline course of at least six weeks only for treatment-naïve primary prostate pain lasting less than one year. Avoid unnecessary antibiotics and consider local resistance; after one unsuccessful six-week course, offer other therapeutic options rather than repeated empirical courses. [1]
  • Use an alpha blocker for primary prostate pain lasting less than one year. NSAIDs may be offered with consideration of long-term harms, a weak recommendation; assess both function and pain and withdraw an ineffective or poorly tolerated trial. [1]
  • Offer acupuncture for primary prostate pain, a strong recommendation. Pregabalin has not demonstrated effective treatment of this syndrome, and the source does not support prostate or bladder-neck surgery for chronic pain in this population. [1]

Escalate bladder-pain treatment by subtype

  • For primary bladder pain, use subtype- and phenotype-directed treatment with behavioural, physical and psychological approaches alongside oral or invasive therapy. EAU recommends amitriptyline and offers oral pentosan polysulphate; dietary advice may be offered, with a weak recommendation. [1]
  • Do not use oral corticosteroids for long-term primary bladder pain treatment. Bladder distension alone is also not recommended as treatment; distinguish its limited therapeutic role from its possible use during diagnostic evaluation. [1]
  • Before more invasive bladder-pain interventions, consider intravesical hyaluronic acid or chondroitin sulphate, alkalinised lidocaine, or heparin alone or in combination. These are weak recommendations; discuss catheter-related pain, infection risk and treatment burden. [1]
  • For primary bladder pain after intravesical instillations fail, consider bladder-wall/trigonal botulinum toxin A with hydrodistension. Neuromodulation may be offered before more invasive intervention, a weak recommendation; invasive neuromodulation requires specialist selection and follow-up. [1]
  • Offer resection, coagulation or laser of bladder lesions only in type 3C primary bladder pain with Hunner lesions, not glomerulations or petechiae. Reserve major ablative or reconstructive surgery for severe refractory disease as a last resort, after multidisciplinary pain assessment at an experienced centre. [1]

Treat pelvic-floor and associated problems

  • For pelvic-floor dysfunction, consider myofascial treatment first-line, a weak recommendation. Specialist physiotherapy should address overactivity and trigger points, including relaxation and stretching when muscles are shortened; do not assume that generic strengthening alone is appropriate. [1]
  • For chronic primary anal pain, use biofeedback, particularly when an overactive pelvic floor is identified. EAU also gives weak recommendations for tibial or sacral neuromodulation, and for inhaled salbutamol in intermittent primary anal pain; these are different phenotypes, not a single interchangeable treatment ladder. [1]
  • For suspected pelvic peripheral-nerve pain, exclude malignancy, infection, trauma and spinal disease and consider early multidisciplinary expert referral. Use established neuropathic-pain approaches for pudendal neuralgia; normal imaging or electrophysiology does not by itself exclude the syndrome. [1]
  • Discuss behavioural strategies with the patient and partner and consider pelvic-floor therapy to improve sexual function and quality of life. Screen sensitively for abuse without implying that it caused the pain; these recommendations are weak. [1]
  • Assess fear, anxiety and depression and ask what the patient believes causes the symptoms. Significant psychological distress warrants pelvic-pain-focused psychological treatment. Distress or multiple symptoms are not evidence that pain is unreal. [1]
  • Refer complications after mesh insertion to a multidisciplinary service including pain medicine and surgery. Removal is complex and may leave pain or cause recurrent incontinence; individual assessment and experienced tertiary care are necessary rather than promising a cure. [1]
  • For ketamine-associated uropathy, cessation and coordinated addiction care are central; established fibrosis or strictures do not reverse. Assess urine culture, renal/liver function and urinary-tract imaging, and refer upper-tract compromise for specialist management while supporting abstinence. [1]

Measure benefit and reassess treatment

  • For persistent pelvic pain, judge analgesic or neuromodulator trials by function and quality of life as well as pain. Titrate against benefit and harms and discontinue ineffective treatment appropriately. Gabapentinoid dependence/misuse risk and limited pelvic-pain-specific evidence require explicit review rather than automatic escalation. [1]
  • For chronic nonacute urogenital pain, prescribe opioids or other dependence-forming drugs only after multidisciplinary assessment and failure of other reasonable treatments. A trained specialist should decide on long-term opioids with the patient and primary clinician; arrange monitoring and involve addiction/pain expertise when misuse is suspected. [1]
  • Review chronic primary visceral-pain treatment after about six weeks. If benefit is insufficient, reassess adherence, adverse effects, function and therapy reports before adapting treatment or referring to a specialist multidisciplinary service. Maintain shared self-management support and plan for recurrence after improvement. [1]

Limitations and use

  • This selected summary does not reproduce every drug option, procedure, phenotype algorithm or disease-specific pathway. It supplies no antibiotic, intravesical, neuropathic-drug or opioid dose regimen; current product safety, contraindications and local resistance guidance require separate assessment. It is not an acute pelvic pain, cancer-pain, endometriosis or opioid-tapering protocol. Pain-syndrome recommendations apply only after appropriate evaluation for treatable causes.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Chronic pelvic pain

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
EAU
Resource type
Clinical guideline · House clinical summary
Source setting
Europe

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Investigate disease and understand the pain phenotype
  • Use selected treatment for primary prostate pain
  • Escalate bladder-pain treatment by subtype
  • Treat pelvic-floor and associated problems
  • Measure benefit and reassess treatment
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House